MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Method for co-culture of stem cells and feeder cells using a polymer membrane

Korea Health Industry Development Institute
This technology is related to optimal conditions for culturing stem cells and feeder cells

Mechanism of action

i) Providing optimal culture surface : tension-related signal pathway is associated with self-renewal and apoptosis

Full description

This technology is related to ideal culture system for hES cells. Difficulties in culture  hinders mass culture of hES cells. Although there have been many efforts to establish feeder-free culture for hES cells, they are expensive and less effective. Feeder cells provide various factors dispensable for hES cells to self-renew which we do not fully understand. Co-culture with feeders is the most efficient and economical way to control self-renewal of hES cells. Nevertheless, co-culture system with feeders has many disadvantages such as possibility of feeder cell contamination, culture fluctuation depending on condition of feeder cells, difficulty in pre-treatment of cytostatic agents or irradiation of feeder cells. However, porous membrane-based co-culture system allows co-culture of hES cells eliminating these difficulties in that :

1)     No feeder cell contamination since this system allows only soluble factor exchanges between hES cells and feeder cells

2)     No need to pre-treat cytostatic agents to arrest growth of feeder cells

3)     No need to coat culture surfaces with extracellular matrix, the main source of xenogene contamination.

4)     Less culture fluctuation due to feeder cell condition

5)     No time limit for sub-culturing depending on feeder cell deaths

6)     Maintaining optimal composition of culture medium for each type of cell

Although membrane-based co-culture system has long been used, it has never been applied for hES cells. Furthermore we found that there is an optimal range of several physical factors and materials of polymer membrane to support undifferentiated state of hES cells maximally. When optimized, we found that membrane-based co-culture system enhanced self-renewal and growth of hES cells far more than conventional culture system as follows:

1)    Reduced spontaneous differentiation

2)    Increased cell production rate due to ~1% of apoptosis comparing to ~20-30% of apoptosis in conventional culture

We further confirmed that genetic and epigenetic stability and differentiation capacity are well maintained when hES cells are cultured on membrane. In this regard this technology can be applied for mass culture of hES cells for drug discovery and therapeutic purposes and for derivation of pluripotent stem cells for human being and animals.

Development status

Early Stage

Patent information

PCT/KR2007/002597 on n29th May 2006

- Korean patent enrollment decided on 20th Feb 2008 (Korean Patent registration No. 10-2006-0077478 on 17th August 2006)

Type of business relationship sought

  - Overseas licensing opportunity

  - Seeking potential corporate partners

Licensing contact

YongU KIM
Business Development Manager
Health Technology Transfer Center

Contact directly

Company details

Korea Health Industry Development Institute

KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us